Verve Therapeutics is a specialized clinical-stage biotechnology and genetic medicine company dedicated to pioneering innovative, single-course gene-editing therapies designed to target the root genetic causes of cardiovascular diseases. Rather than relying on traditional chronic management pharmaceuticals that require lifelong dosing, Verve focuses on advanced in vivo gene editing technologies—such as base editing—to permanently modify disease-driving genes like PCSK9 and ANGPTL3, aiming to transform high-risk lipid management into a permanent, one-time preventative solution for patients globally.